- WuXi Biologics has installed three new sets of 5,000L single-use bioreactors at its MFG20 drug substance manufacturing facility in Hangzhou, China, increasing the capacity from 8,000L to 23,000L.
- The new single-use bioreactors are expected to complete good manufacturing practice (GMP) release later in 2024.
WuXi Biologics, a contract research, development and manufacturing organisation (CRDMO), has successfully installed three new sets of 5,000L single-use bioreactors at its MFG20 drug substance manufacturing facility in Hangzhou, China. This move enhances the manufacturing capability at the site by increasing capacity from 8,000L to 23,000L.
Single-use bioreactors offer flexible and cost-effective manufacturing and are more environmentally sustainable with reduced contamination risk, compared with stainless steel bioreactors, according to the company. Utilising the larger reactor improves manufacturing efficiency by lowering the number of production batches and decreases production cost by reducing equipment, labour, and material consumption.
The new single-use bioreactors at the Hangzhou facility are expected to complete good manufacturing practice (GMP) release later in 2024.
“The addition of 5,000L single-use bioreactors is a major milestone in our company’s offerings, as we enhance capacity and capability to meet the needs of our clients,” said Dr Chris Chen, CEO of WuXi Biologics. This development marks a significant step in the company’s growth and its commitment to providing efficient and sustainable solutions in the field of contract manufacturing.
Overview of outsourcing trends 
